<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">15486558</PMID>
        <DateCompleted>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0929-1903</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer gene therapy</Title>
                <ISOAbbreviation>Cancer Gene Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>35-45</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The success of surgery to remove primary tumors can be compromised by the subsequent outgrowth of metastases. It is recognized that primary tumors secrete antiangiogenic factors that suppress the outgrowth of their daughter metastases. In accord we show here that surgical removal of primary EL-4 lymphomas led to a marked decrease in the levels of circulating angiostatin and endostatin, and promoted the growth of distant nodular tumors. Expression vectors encoding angiostatin and endostatin, formulated with poly-N-vinyl pyrrolidone (PVP), were injected into the tibialis and gastrocnemia muscles, leading to expression of angiostatin and endostatin in muscle fibers. High levels of biologically active exogenous proteins were secreted into the circulation. Intramuscular gene therapy with angiostatin and endostatin plasmids significantly inhibited tumor vascularity and induced tumor cell apoptosis, and thereby suppressed the growth of secondary subcutaneous and disseminated metastatic tumors in the lung and liver. Simultaneous intramuscular delivery of both angiostatin and endostatin plasmids significantly prolonged the survival of mice after removal of primary tumors. These results suggest that intramuscular gene transfer of angiostatin and endostatin might serve as a prophylactic cancer-prevention strategy to combat the recurrence of cancer after surgical resection of primary tumors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Xueying</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Qilu Hospital, Shandong University, Jinan 250012, China. k.sun@auckland.ac.nz</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiao</LastName>
                    <ForeName>Haiquan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Hongchi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhi</LastName>
                    <ForeName>Xuting</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Fengjun</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jianli</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Meng</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Dianning</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanwar</LastName>
                    <ForeName>Jagat R</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Ruian</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krissansen</LastName>
                    <ForeName>Geoffrey W</ForeName>
                    <Initials>GW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cancer Gene Ther</MedlineTA>
            <NlmUniqueID>9432230</NlmUniqueID>
            <ISSNLinking>0929-1903</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043169">Endostatins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>86090-08-6</RegistryNumber>
                <NameOfSubstance UI="D043168">Angiostatins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D043168" MajorTopicYN="N">Angiostatins</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D043169" MajorTopicYN="N">Endostatins</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008223" MajorTopicYN="N">Lymphoma</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013953" MajorTopicYN="N">Thymus Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>10</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15486558</ArticleId>
            <ArticleId IdType="pii">7700766</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.cgt.7700766</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
